Digestery
Longevity supplements › NMN and Aging › Studies

Randomized trial · measured other health measures

A 60-day trial of NMN in 80 healthy middle-aged adults found longer walking distance

Yi and colleagues · GeroScience · 2023

Original title: The efficacy and safety of β-nicotinamide mononucleotide (NMN) supplementation in healthy middle-aged adults: a randomized, multicenter, double-blind, placebo-controlled, parallel-group, dose-dependent clinical trial.

Under review. A person has not yet checked this summary against the paper. It is written from the PubMed abstract. Until a person checks it, search engines are asked not to list this page.

What the study found

Points to benefit

Blood NAD rose in all NMN groups (all p ≤ 0.001). Six-minute walk distance was higher than placebo (all p < 0.01). Blood-based biological age rose in placebo and stayed unchanged with NMN. No safety issues.

The study at a glance

Type of study
Randomized trial
Who or what was studied
80 people · Healthy middle-aged adults
What was tested
NMN 300, 600 or 900 mg a day for 60 days, vs placebo
What it measured
Several kinds of outcomes
Daily amount
900 mg a day
How long
9 weeks
Trial registration
NCT04823260, CTRI/2021/03/032421
Who has a stake
Company stake
One author works for Abinopharm and two for Aba Chemicals.
Journal
GeroScience, 2023
Source
PubMed record 36482258. This page is based on the abstract only.

How much this study counts

  • ✓Randomized: people were put into groups by chance, so the groups start out alike.
  • ✓Compared with a placebo, a dummy treatment.
  • •Medium size: 80 people.
  • –Short: 9 weeks. Longer-term effects are unknown.
  • •Measured several kinds of outcomes.
  • –Company stake: One author works for Abinopharm and two for Aba Chemicals.
  • •Summarized from the PubMed abstract only. The full paper may hold details the abstract leaves out.

✓ Strength– Limit• Note

These points come from fixed rules about the type of study, its size and length, what it measured, and who has a stake. Every study on Digestery gets the same rules.

Where this study sits

Each dot is one on-topic paper on this question. Steps near the top answer the question more directly.

↑ Stronger evidence

  1. Trials in people: aging and age-related decline

    0

    Not done yet. This is the step that would answer the question.

  2. Trials in people: other measures

    9

    3 benefit, 2 mixed, 4 no difference

    ↑ This study is the ringed dot

  3. Trials in people: lab tests or safety

    7

    4 benefit, 1 mixed, 2 no difference

  4. Population studies

    0

    None among the papers we read.

  5. Blood levels and genes

    0

    None among the papers we read.

  6. Animals

    6

    5 benefit, 1 mixed

↓ Weaker evidence

  • Points to benefit
  • Mixed
  • No difference
  • No direction
  • Points to harm

How it fits with the other research

The short answer to “Does NMN slow aging?”

Not shown in people so far.

Confidence: very low. Based on 29 on-topic papers.

Read the full answer

Of the other 8 papers on the same step: 2 benefit, 2 mixed, 4 no difference. This one found benefit.

Other papers on the same step

See all 29 studies on this question

How this page was made

Label

First read of the abstract
Claude Sonnet
Independent second read
Claude Haiku
Differences settled
The two reads agreed on every checked field. Claude Opus 5.5.
Headline
Claude Sonnet, from the checked study record. A script checked its numbers and wording.
Numbers
Checked against the abstract by a script
“How much this study counts”
Fixed rules, the same for every study
Source check by a person
Not yet. Required before search engines may list this page.

Spot an error? Email a flag with a link to your source, or use the form on the question page.